Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ESG206

Phase 2Small molecule

SShanghai Escugen Biotechnology Co., Ltd

ESG206 is one of 63 small molecule programs targeting Sjogren syndrome. It is currently in Phase 2.

2

Indications

4

Total Trials

2

Active Trials

62

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sjogren SyndromeActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Sjogren SyndromePhase 2

Active, not recruiting

Immune ThrombocytopeniaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Nplate

Rysodeg

Cellcept

Vyvgart

Doptelet

Fabhalta

Johnson & Johnson

Wayrilz

GGenzyme, a Sanofi Company

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Avlosulfon

AAlmirall, S.A.

Tamiflu

CConrado Roberto Hoffmann Filho

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Immune Thrombocytopenia

NCT06853444

Q2 2028

Phase 2Not yet recruiting

Sjogren Syndrome

NCT07375524

Clinical

Trials by Indication[1]

B-cell Lymphoid Malignancies2 trials

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Completed·SShanghai Escugen Biotechnology Co., Ltd·Phase 1·NCT05822843·13 enrolled

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

Withdrawn·SShanghai Escugen Biotechnology Co., Ltd·Phase 1·NCT05263739

Sjogren syndrome1 trial

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Not yet recruiting·SShanghai Escugen Biotechnology Co., Ltd·Phase 2·NCT07375524·40 enrolled

Immune Thrombocytopenia1 trial

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

Recruiting·SShanghai Escugen Biotechnology Co., Ltd·Phase 1/2·NCT06853444·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ESG206. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESG206 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESG206. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Escugen Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Escugen Biotechnology Co., Ltd

Related News